Skip to main content
  • Neuroscientists discover a new drug candidate for treating epilepsy Pradip Mahajan Tue, 11/29/2022 - 16:12

    Temporal lobe epilepsy (TLE) is one of the most common types of epilepsy worldwide. Although symptomatic medications are available, one-third of TLE patients remain unresponsive to current treatment, so new drug targets are critically needed. A research team co-led by a City University of Hong Kong (CityU) neuroscientist recently identified and developed a new drug candidate that has potential for effectively treating TLE by suppressing neuroinflammation.

  • Chemotherapy could increase disease susceptibility in future generations Pradip Mahajan Tue, 11/29/2022 - 16:06

    A common chemotherapy drug could carry a toxic inheritance for children and grandchildren of adolescent cancer survivors, Washington State University-led research indicates.

  • Discovery could lead to new drugs to block protein that fuels bowel cancer Pradip Mahajan Mon, 11/28/2022 - 16:02

    Scientists have revealed the inner workings of a key protein involved in a wide range of cellular processes – potentially paving the way for better and less toxic cancer drugs.

    Using Nobel Prize-winning microscopy techniques, the researchers revealed how the tankyrase protein switches itself on and off by self-assembling into 3D chain-like structures.

  • AI tailors artificial DNA for future drug development Pradip Mahajan Mon, 11/28/2022 - 15:57

    With the help of artificial intelligence, researchers at Chalmers University of Technology, Sweden, have succeeded in designing synthetic DNA that controls the cells' protein production. The technology can contribute to the development and production of vaccines, drugs for severe diseases, as well as alternative food proteins much faster and at significantly lower costs than today.

  • Covid-19 : the Spike protein is no longer the only target Pradip Mahajan Tue, 11/22/2022 - 17:10

    With the continuous emergence of new variants and the risk of new strains of the virus, the development of innovative therapies against SARS-CoV-2 remains a major public health challenge. Currently, the proteins that are on the surface of the virus and/or are involved in its replication are the preferred therapeutic targets, like the Spike protein targeted by vaccines. One of them, the non-structural protein Nsp1, had been little studied until now.

  • Flu shots can protect patients with heart failure from death

    Flu shots can save the lives of people with cardiovascular disease by reducing cardiac complications as well as preventing influenza.

    An international study led by McMaster University researchers and published in The Lancet Global Health has found that influenza vaccines greatly reduce both pneumonia and cardiovascular complications in people with heart failure.

  • Enzymes could be key to understanding how DNA mutates, quantum biologists find

    Enzymes, which are crucial to controlling how cells replicate in the human body, could be the very ingredient that encourages DNA to spontaneously mutate – causing potentially permanent genetic errors, according to new research from the University of Surrey.

  • Researchers Design Prodrug That Targets Cancer Cells

    Johns Hopkins Medicine researchers have revamped an anti-cancer drug to better target cancer cells and leave healthy tissues unharmed. Scientists have dubbed this type of targeted approach a “prodrug” — a medicine designed to release its payload in a particular area of the body and in no other areas. The Johns Hopkins-discovered prodrug, called DRP-104 (sirpiglenastat), is in early-stage clinical trials in people with advanced solid tumors.

  • Study unveils protein synthesis in red blood cells

    The process by which the mRNA codes for a particular protein is known as translation. It is the final step in which an mRNA carrying information from DNA synthesises proteins. It is a necessary process performed by almost all living cells, leaving erythrocytes (Reb Blood Cells or RBCs), which are believed to be the only exception. A research team led by Sandeep M Eswarappa, Associate Professor, Department of Biochemistry, Indian Institute of Science, Bengaluru, has identified that mature human RBCs can also make their proteins.

  • Potential new lead compounds for the treatment of depression and anxiety disorders

    Currently, various classes of drugs are available for the treatment of mental illnesses - such as depression and anxiety disorders. However, although these drugs confer benefits, they are also associated with adverse side-effects. Conseqeuntly, medical researchers continuously thrive to improve the pharmacological properties of therapeutic agents to optimize the benefit-to-side-effect ratio.

Subscribe to Research News

Search this website